{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:15:47Z","timestamp":1757780147469,"version":"3.41.2"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Syndrome of inappropriate antidiuresis (SIAD) is one of the most frequent causes of euvolemic hyponatremia (serum sodium levels &amp;lt; 135 mEq\/L) and it represents more than 35% of hyponatremia cases in hospitalized patients. It is characterized by an inappropriate vasopressin (AVP)\/antidiuretic hormone (ADH) secretion, which occurs independently from effective serum osmolality or circulating volume, leading to water retention via its action on type 2 vasopressin receptor in the distal renal tubules. Corpus callosum agenesis (CCA) is one of the most common congenital brain defects, which can be associated to alterations in serum sodium levels. This report presents a rare case of chronic hyponatremia associated with SIAD in a woman with CCA, whose correction of serum sodium levels only occurred following twice-daily tolvaptan administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 30-year-old female was admitted to our hospital for non-acute hyponatremia with dizziness, headache, distal tremors, and concentration deficits. She had profound hyponatremia (Na 121 mmol\/L) with measured plasma hypo-osmolality (259 mOsm\/Kg) and urinary osmolality greater than 100 mOsm\/Kg (517 mOsm\/Kg). She presented clinically as normovolemic. After the exclusion of other causes of normovolemic hyponatremia, such as hypothyroidism and adrenal insufficiency, a diagnosis of SIAD was established. We have ruled out paraneoplastic, inflammatory, and infectious causes, as well as ischemic events. Her medical history showed a CCA and frontal teratoma. We administered tolvaptan initially at a low dosage (15 mg once a day) with persistence of hyponatremia. Therefore, the dosage was first doubled (30 mg once a day) and then increased to 45 mg once a day with an initial improvement in serum sodium levels, although not long-lasting. We therefore tried dividing the 45 mg tolvaptan administration into two doses of 30 mg and 15 mg respectively, using an off-label treatment schedule, thus achieving long-lasting serum sodium levels in the low-normal range associated with a general clinical improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This report underlines the importance of the correct diagnosis, management and treatment of SIAD, as well as the need for further studies about the pharmacokinetics and pharmacodynamics of vasopressin receptor antagonists.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1309657","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:27:40Z","timestamp":1705292860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD"],"prefix":"10.3389","volume":"14","author":[{"given":"Anna","family":"Arecco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Demontis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Della Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natale","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(57)90224-3","article-title":"A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone","volume":"23","author":"Schwartz","year":"1957","journal-title":"Am J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000324653","article-title":"The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options","volume":"119","author":"Esposito","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042743","article-title":"Nephrogenic syndrome of inappropriate antidiuresis","volume":"352","author":"Feldman","year":"2005","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.380","article-title":"Mild hyponatremia as a risk factor for fractures: The rotterdam study","volume":"26","author":"Hoorn","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(03)00004-5","article-title":"Evaluation and management of hypo-osmolality in hospitalized patients","volume":"32","author":"Janicic","year":"2003","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatremia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6299.1081","article-title":"Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone","volume":"283","author":"Decaux","year":"1981","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"R184","DOI":"10.1186\/cc9292","article-title":"Treatment of euvolemic hyponatremia in the intensive care unit by urea","volume":"14","author":"Decaux","year":"2010","journal-title":"Crit Care"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1982.03320290017021","article-title":"Rapid correction with urea, sodium chloride, and water restriction therapy","volume":"247","author":"Decaux","year":"1982","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0b013e3181f5b3b7","article-title":"Novel agents for the treatment of hyponatremia: A review of conivaptan and tolvaptan","volume":"18","author":"Ferguson-Myrthil","year":"2010","journal-title":"Cardiol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1006-7","article-title":"Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)","volume":"67","author":"Gassanov","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.4158\/EP10386.CR","article-title":"Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose","volume":"17","author":"Torres","year":"2011","journal-title":"Endocrine Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2009.03.002","article-title":"The treatment of hyponatremia","volume":"29","author":"Sterns","year":"2009","journal-title":"Semin Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.08.179","article-title":"Agenesis of the corpus callosum","volume":"223","author":"Rotmensch","year":"2020","journal-title":"Am J Obstetrics Gynecology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.earlhumdev.2017.10.004","article-title":"Neurodevelopmental outcome in prenatally diagnosed isolated agenesis of the corpus callosum","volume":"116","author":"Folliot-Le Doussal","year":"2018","journal-title":"Early Hum Dev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10090625","article-title":"Corpus callosum agenesis: an insight into the etiology and spectrum of symptoms","volume":"10","author":"Hofman","year":"2020","journal-title":"Brain Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/adc.70.1.51","article-title":"Diabetes insipidus with impaired osmotic regulation in septo-optic dysplasia and agenesis of the corpus callosum","volume":"70","author":"Masera","year":"1994","journal-title":"Arch Dis Childhood"},{"key":"B19","first-page":"51","article-title":"Septo-optic dysplasia","volume-title":"Handbook of Clinical Neurology","author":"Sataite","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2000.13.9.1637","article-title":"Hyponatremia secondary to reset osmostat in a child with a central nervous system midline defect and a chromosomal abnormality","volume":"13","author":"Gupta","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80601-0","article-title":"Chronic reset osmoreceptor response, agenesis of the corpus callosum, and hypothalamic cyst","volume":"104","author":"Bannister","year":"1984","journal-title":"J Pediatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-023-04472-5","article-title":"Tolvaptan for treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a child with corpus callosum agenesis","author":"Meena","year":"2023","journal-title":"Indian J Pediatr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.911810","article-title":"Chronic hyponatremia due to the syndrome of inappropriate antidiuresis (SIAD) in an adult woman with corpus callosum agenesis (CCA)","volume":"19","author":"Silveira","year":"2018","journal-title":"Am J Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3822","article-title":"Cerebral falx mature teratoma with rare imaging in an adult","volume":"9","author":"Zhao","year":"2012","journal-title":"Int J Med Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4102\/sajpsychiatry.v22i1.924","article-title":"Treated for psychosis and presenting with prominent speech and language abnormalities: A case report of an adult with a frontal lobe teratoma","volume":"22","author":"Lippi","year":"2016","journal-title":"S Afr J Psych"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000180899.24865.b6","article-title":"Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure","volume":"46","author":"Hauptman","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12465","article-title":"The diagnosis and management of inpatient hyponatremia and SIADH","volume":"45","author":"Grant","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016101139","article-title":"Diagnosis and treatment of hyponatremia: compilation of the guidelines","volume":"28","author":"Hoorn","year":"2017","journal-title":"JASN"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa619","article-title":"Fluid restriction therapy for chronic SIAD; results of a prospective randomized controlled trial","volume":"105","author":"Garrahy","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12532","article-title":"Predictors of nonresponse to fluid restriction in hyponatremia due to the syndrome of inappropriate antidiuresis","volume":"280","author":"Winzeler","year":"2016","journal-title":"J Intern Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0026-0495(88)90028-5","article-title":"Effect of protein intake and urea on sodium excretion during inappropriate antidiuresis in rats","volume":"37","author":"Verbalis","year":"1988","journal-title":"Metabolism"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000336716","article-title":"Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients","volume":"35","author":"Coussement","year":"2012","journal-title":"Am J Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1974.37","article-title":"Effects of demethyichiortetracycline on cellular action of antidiuretic hormone in vitro","volume":"5","author":"Dousa","year":"1974","journal-title":"Kidney Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm3041276","article-title":"Review of tolvaptan\u2019s pharmacokinetic and pharmacodynamic properties and drug interactions","volume":"3","author":"Bhatt","year":"2014","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12943","article-title":"Real-life experience of tolvaptan use in the treatment of severe hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion","volume":"84","author":"Tzoulis","year":"2016","journal-title":"Clin Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab131","article-title":"Clinical experience of the efficacy and safety of low-dose tolvaptan therapy in a UK tertiary oncology setting","volume":"106","author":"Chatzimavridou-Grigoriadou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1959.02340140020004","article-title":"Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients","volume":"81","author":"Adams","year":"1959","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0600","article-title":"Central pontine myelinosis and osmotic demyelination syndrome","volume":"116","author":"Lambeck","year":"2019","journal-title":"Deutsches \u00c4rzteblatt Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1053\/j.sult.2013.09.009","article-title":"Osmotic demyelination syndrome: central pontine myelinolysis and extrapontine myelinolysis","volume":"35","author":"Alleman","year":"2014","journal-title":"Semin Ultrasound CT MRI"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"New Engl J Med"},{"unstructured":"FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death2013","key":"B43"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"JASN"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial","volume":"34","author":"Refardt","year":"2023","journal-title":"JASN"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2302-7","article-title":"Low-dose tolvaptan PK\/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults","volume":"73","author":"Shoaf","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100910","article-title":"Syndrome of inappropriate antidiuretic hormone secretion associated with an ovarian immature teratoma: A case report and review of the literature","volume":"39","author":"Hom-Tedla","year":"2022","journal-title":"Gynecologic Oncol Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1309657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:27:44Z","timestamp":1705292864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1309657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":49,"alternative-id":["10.3389\/fendo.2023.1309657"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1309657","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"1309657"}}